Ponatinib-induced neutrophilic panniculitis
- PMID: 24602068
- DOI: 10.1111/cup.12326
Ponatinib-induced neutrophilic panniculitis
Abstract
Ponatinib is a bcr-abl tyrosine-kinase inhibitor (TKI) used to treat resistant and refractory chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia that express bcr-abl. Neutrophilic panniculitis has been described in rare cases of patients on other TKIs in the same class as ponatinib. We present the first case of neutrophilic panniculitis following treatment with ponatinib and summarize the other cases of panniculitis caused by TKIs.
Keywords: chronic myeloid leukemia; drug reaction; panniculitis; ponatinib.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
